Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemetrexed + volasertib
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of pemetrexed, an antifolate antimetabolite chemotherapy agent, and volasertib, a potent and selective Polo-like kinase (PLK) inhibitor. This combination was investigated for the treatment of non-small cell lung cancer (NSCLC).
- Brand names
- ALIMTA
- Other names
- volasertib + pemetrexed
02
Targets
DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)PLK1 (Polo like kinase 1)
Beyond the preview
Go deeper on pemetrexed + volasertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemetrexed + volasertib.